to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

NCT ID: NCT04593511

Last Updated: 2021-06-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-02
• Study Completion Date: 2021-10-31

Brief Summary

The purpose of this study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers.

Detailed Description

This is an open-label study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of four formulations of LY03009 (F1, F2, F3, F4) after a single intramuscular injection.

Approximately 40 healthy subjects are planned to be enrolled in this study and assigned to four cohorts (F1, F2, F3, F4) sequentially, 10 subjects per group at a fixed dose of 112 mg for F1~F3 and 224 mg for F4. Each subject will receive only one dose in this study.

Conditions

Parkinson's Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Formulation 1

a single dose of LY03009 F1

Group Type: EXPERIMENTAL

LY03009 F1

Intervention Type: DRUG

a single dose of LY03009 F1

Formulation 2

a single dose of LY03009 F2

Group Type: EXPERIMENTAL

LY03009 F2

Intervention Type: DRUG

a single dose of LY03009 F2

Formulation 3

a single dose of LY03009 F3

Group Type: EXPERIMENTAL

LY03009 F3

Intervention Type: DRUG

a single dose of LY03009 F3

Formulation 4

a single dose of LY03009 F4

Group Type: EXPERIMENTAL

LY03009 F4

Intervention Type: DRUG

a single dose of LY03009 F4

Interventions

LY03009 F1

a single dose of LY03009 F1

Intervention Type: DRUG

LY03009 F2

a single dose of LY03009 F2

Intervention Type: DRUG

LY03009 F3

a single dose of LY03009 F3

Intervention Type: DRUG

LY03009 F4

a single dose of LY03009 F4

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Willing and capable of giving signed written informed consent;

2. Male or female, 18-65 years of age (inclusive) at screening;

3. Body mass index (BMI, weight [kg]/height [m]2) between 18.0 and 30.0 kg/m2, inclusive;

4. The screening results within the normal range or outside the normal range but assessed as clinically non-significant by the Investigator based on detailed medical history, clinical laboratory tests, vital signs, physical examination, and 12-lead ECG; QTcF ≤450 msec for male subjects, and QTcF ≤470 msec for female subjects.

5. Males who are willing to remain abstinent; or if engaging in sexual intercourse with a female partner of childbearing potential, willing to use a condom in addition to having the female partner use a highly effective method of contraception throughout the study and until at least 3 months after the end of the study. This requirement does not apply to subjects in a same sex relationship or subjects with female partners of non-childbearing potential. Male subjects must also be willing to not donate sperm throughout the study and until at least 3 months after the end of the study.

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from the study:

1. With history of history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, neurologic, bronchopulmonary, immunologic, and/or lipid metabolism disorders, and/or drug hypersensitivity, or any other condition that, in the opinion of the PI, would jeopardize the safety of the subject, affect the validity of the study results, or impair the ability to provide informed consent;

2. Hospital admission or major surgery within 3 months prior to screening, or plan to have surgery before the completion of study;

3. Receipt of another investigational product within 1 month or 5 half-lives of the other investigational product, whichever is longer, before study drug administration in this study;

4. Unwillingness or inability to comply with food and beverage restrictions during study participation;

5. Have a history of significant drug sensitivity or drug allergy, or known hypersensitivity to the study drugs, the metabolite or formulation excipients;

6. Malignancy within 5 years of screening visit (excluding non-melanoma skin cancer and cervical carcinoma in situ that has been completely resected);

7. Subject who is considered unsuitable for participating in the study in the opinion of investigator.

8. Recent administration of live vaccine within 3 months prior to dosing and until at least 30 days after the completion of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Luye Pharma Group Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Angela Molga

Role: PRINCIPAL_INVESTIGATOR

CMAX Clinical Research Pty Ltd

Locations

CMAX clinical Research Pty Ltd

Adelaide, South Australia, Australia

Countries

Australia

Other Identifiers

LY03009/CT-AUS-101

Identifier Type: -

Identifier Source: org_study_id